Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Nichi-Iko Pharmaceutical Co Ltd
Cost of Revenue
Nichi-Iko Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
Cost of Revenue
-¥175.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.4T
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥415.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥626.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥334.9B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥292.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
See Also
What is Nichi-Iko Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-175.1B
JPY
Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Cost of Revenue amounts to -175.1B JPY.
What is Nichi-Iko Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-9%
Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for Nichi-Iko Pharmaceutical Co Ltd have been -9% over the past three years , -9% over the past five years .